9 results for "Purnima Pathak"
Showing 1–9 · 0.51 seconds · RSS
-
Journal Article
Molecular diversity analysis of rough lemon (Citrus jambhiri Lush.) in different agroclimatic zones of Assam
Rough lemon (Citrus jambhiri Lush.) is an important rootstock in Citrus group. Being indigenous to North-Eastern part of India, a wide variability has been observed in the region particularly in the state of Assam. However, not much evolved types have been reported in due course of time. SSR…
-
Journal Article Full text
Effect of ribociclib on productivity losses due to breast cancer in young women in Brazil
ABSTRACT OBJETIVE To evaluate the effect of ribociclib versus endocrine therapy on productivity losses due to advanced breast cancer. METHODS Productivity data from the MONALEESA-7 trial, obtained from the results of the application of the Work Productivity and Activity Impairment (WPAI)…
-
Journal Article
Patients' perspectives on COPD: findings from a social media listening study
We utilised social media listening (SML) to obtain patients' perspectives on symptoms, diagnosis and comorbidities associated with chronic obstructive pulmonary disease (COPD) and its impact on patients' quality of life (QoL). A comprehensive search on social media platforms was performed for…
-
Journal Article
Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole palbociclib plus letrozole as first-line treatment of HR+/HER2− advanced breast cancer
Background: Current standard-of-care first-line treatment of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC) is cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + endocrine therapy. In the MONALEESA-2 trial…
-
Journal Article
Quality of life with ribociclib abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison
Background: A cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + endocrine therapy is recommended as first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC). Quality of life (QoL) is an important endpoint that…
-
Journal Article
Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer
Abstract (246 words): Background: Despite adjuvant endocrine therapy (ET), recurrence is still a concern for patients with HR+/HER2- early breast cancer (EBC). We assessed recurrence risk in real-world patients with stage II/III HR+/HER2- EBC treated with adjuvant ET. Methods: A retrospective…
-
Journal Article
Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2− advanced breast cancer
Background: The phase III MONALEESA-7 trial (NCT02278120) assessed ribociclib + endocrine therapy (ET) versus ET in premenopausal women with HR+/HER2− advanced breast cancer (ABC). The relationship between work productivity loss (WPL) and domains of European Organisation for Research and Treatment…
-
Journal Article
Development and content validation of a self-completed, electronic Pediatric Asthma Symptom Diary
Abstract Background Childhood asthma is an important unmet need. To date, patient-reported outcome measures (PROMs) for children with asthma have used a combination of caregiver or proxy-reported and self-reported measures. No comprehensive measure is available to assess the severity and impact of…